Cancer, Solid tumor/s, Neurofibromatosis type 1 

Cancer, Blood cancer, Chronic lymphocytic leukemia, Small lymphocytic lymphoma 

PTEN-Deficient Metastatic Hormone-Sensitive Prostate Cancer

Early-stage HER2+ breast cancer (neoadjuvant)

Cancer, Non-small cell lung carcinoma, Lung cancer

Cancer, Gastroesophageal junction tumors, Gastric cancer

HER2-Positive Early Breast Cancer With Residual Disease After Neoadjuvant Therapy

High-Risk Non-Muscle-Invasive Bladder Cancer

Solid tumor/s, Cancer, Castration-resistant prostate cancer

Non-small cell lung carcinoma, Cancer, Lung cancer

Rare diseases, Myasthenia gravis, Paroxysmal nocturnal hemoglobinuria , Atypical haemolytic uraemic syndrome, Neuromyelitis optica spectrum disorder (NMOSD)

Lung cancer, Cancer, EGFR-mutated advanced lung cancer

Lung cancer, Cancer, Small cell lung cancer

Myasthenia gravis, Paroxysmal nocturnal hemoglobinuria , Atypical haemolytic uraemic syndrome

Cancer, Solid tumor/s, Endometrial cancer

Cancer, Blood cancer, Chronic lymphocytic leukemia

Cancer, Blood cancer, Mantle cell lymphoma

1L HER2-positive Metastatic Breast Cancer

Coronary Microvascular Dysfunction,  Eosinophilic granulomatosis with polyangiitis

Respiratory syncytial virus, Respiratory virus, Viral infection

Respiratory conditions, Acute respiratory distress syndrome, Lung disease

MET-Positive Advanced Papillary Renal Cell Carcinoma

Claudin 18.2-Positive Advanced Gastric, Gastroesophageal Junction, Or Esophageal Adenocarcinoma (Second-Line And Later)

Cancer, Non-small cell lung carcinoma (1L NSCLC)

Muscle-Invasive Bladder Cancer (Cisplatin-Ineligible Or Declined)

Extensive-Stage Small Cell Lung Cancer (First-Line Maintenance)

Claudin 18.2-Positive Advanced Gastric, Gastroesophageal Junction, Or Esophageal Adenocarcinoma (First-Line)

Breast cancer, Cancer, Triple-negative breast cancer 

TROP2 NMR-Positive Advanced Nonsquamous NSCLC

HER2-Expressing Advanced Epithelial Ovarian Cancer

High-Risk Muscle-Invasive Urothelial Cancer (Adjuvant, Post-Surgery)

Metastatic Urothelial Carcinoma (Post Enfortumab Vedotin Plus Pembrolizumab)

Cancer, Chronic kidney disease, Heart failure

Recurrent Or Metastatic Head And Neck Squamous Cell Carcinoma

Resectable, early-stage (stage IIA-IIIB) NSCLC

MET-Amplified Gastric Cancer Or Gastroesophageal Junction Adenocarcinoma

Non-small cell lung carcinoma, Cancer, Lung cancer, Solid tumor/s, Triple-negative breast cancer 

Methylmalonic acidemia, Genetic disorder, Rare genetic disease

Relapsed Or Metastatic B7-H4-Positive Endometrial Cancer And Ovarian Cancer

Relapsed Or Metastatic B7-H4-Positive Endometrial And Ovarian Cancer

Relapsed Or Refractory Classic Hodgkin Lymphoma

TP53 R175H-Mutated Unresectable, Advanced Or Metastatic Solid Tumors

TP53 R175H-Mutated Unresectable Advanced Or Metastatic Solid Tumors

AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.

AZN · Astrazeneca